Analyzing urologists’ 2021 MIPS performance
Here’s how the specialty fared vs other eligible clinicians.
Clearing up confusion surrounding percutaneous nephrolithotomy coding
"Although payers are supposed to adopt CPT instructions, we unfortunately do not have a system that contractually binds payers to follow CPT instructions verbatim," write Jonathan Rubenstein, MD, and Mark Painter.
The perils of GME from the faculty point of view
"The need for maintaining the high quality of education within the increasing number of restrictions and regulations is making the job as program director complex and time-consuming," writes Gopal H. Badlani, MD.
Malpractice Consult: Breaking down what a trial is (and isn’t)
What plays out in real-life courtrooms differs greatly from those on television.
Study shows benefit of PSMA-PET imaging before radical prostatectomy
Clinical guidelines currently do not recommend PSMA-PET imaging before radical prostatectomy.
Intravesical gemcitabine/docetaxel for NMIBC appears safe and efficacious
The current study is welcome news as it lends further support to the use of intravesical Gem/Doce as a safe and effective option that has the potential to become a new standard of care for high-risk NMIBC.
Failure to control lifestyle creep can lead to long-term consequences
Resist the temptation to overspend on unnecessary luxuries and upgrades.
FDA approves pembrolizumab/enfortumab vedotin for frontline urothelial cancer
The approval of pembrolizumab plus enfortumab vedotin in urothelial cancer was supported by results from the EV-103/KEYNOTE-869 trial.
Once-daily apalutamide tablet available for men with prostate cancer
Apalutamide is approved by the FDA for the treatment of patients with non-metastatic castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer.
FDA grants full approval to pembrolizumab for MSI-H/dMMR solid tumors, including genitourinary cancers
Prostate cancer, bladder cancer, renal cell carcinoma were among the multitude of tumor types assessed in the analysis supporting the approval.
Cxbladder Monitor testing found to reduce frequency of cystoscopy for patients with NMIBC
No CxM-negative patients had findings of a recurrent tumor on a follow-up cystoscopy.
Dr. Dukhovny on contract negotiation advice for women physicians
"If I had to boil down the advice, I would say that the most important thing that I did not know, that I've learned over time, is that you have to be prepared," says Stephanie Dukhovny, MD.
Racial and ethnic disparities observed in patients undergoing pelvic organ prolapse surgery
Black race was identified as an independent predictor of 30-day readmission even after investigators controlled for differences in patient demographics, clinical factors, and comorbidities.
2 Clarke Drive Cranbury, NJ 08512